Svetlana Masalovich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Svetlana Masalovich has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Angela Danielle Iuliano
Influenza Division Centers for Disease Control and Prevention Atlanta Georgia USA
1 shared publication - Anthony Scott Laney
Respiratory Health Division, National Institute for Occupational Safety and Health, Morgantown, West Virginia, USA
1 shared publication Anup Srivastav
Leidos, Inc., Atlanta, Georgia
1 shared publication- Bryce D. Smith
Carsone Kids Inc
1 shared publication Carla L. Black
CDC COVID-19 Response, Atlanta, Georgia; Centers for Disease Control and Prevention, Atlanta, Georgia
1 shared publicationCarrie Reed
Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention , Atlanta, Georgia
1 shared publication
Latest Publications
- 1 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
Antiviral Dispensing for Influenza Outpatients Younger Than 65 Years With Comorbidities: A Retrospective Cohort Study
Background: Real-world evidence on antiviral dispensing for influenza outpatients with underlying medical conditions (UMCs) is limited. We characterized dispensing among influenza outpatients aged <65 years with UMCs, comparing commercial and Medicaid coverage. Methods: We used outpatient encounter claims from the US MarketScan Commercial and Medicaid databases during October–April of the 2018–2019 through 2023–2024 influenza seasons and October–December 2024–2025. Eligible encounters included patients aged <65 years with a clinical influenza diagnosis, ≥1 UMC, and ≥12 months of continuous enrollment before diagnosis. Antiviral treatment was defined as dispensing of oseltamivir, peramivir, zanamivir, or baloxavir within 7 days of the encounter. We described demographic, clinical, and care-seeking characteristics and evaluated overall and same-day dispensing by insurance type. Results: Among 549 424 encounters, 268 463 (48.9%) were commercially insured (median age 19 years [interquartile range, IQR, 8–44]) and 280 961 (51.1%) were Medicaid insured (median age 10 years [IQR 5–18]). Chronic pulmonary disease was the most common UMC (88.0% and 81.8%). Antivirals were dispensed in 54.2% (commercial) and 53.7% (Medicaid) of encounters, almost exclusively oseltamivir. Same-day dispensing occurred in 91.1% of commercial and 81.4% of Medicaid encounters. Overall dispensing was lowest among patients with emergency department encounters or multiple outpatient visits; same-day dispensing was lowest among those with multiple UMCs, emergency department encounters, or multiple visits. Dispensing increased with age in commercial encounters but declined among adults with Medicaid. Conclusions: About half of higher-risk influenza outpatients received antivirals. Overall dispensing was similar by insurance type, but Medicaid patients and those with multiple UMCs had greater delays.
- 1 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
Antiviral Dispensing for Influenza Outpatients Younger Than 65 Years With Comorbidities: A Retrospective Cohort Study
Background: Real-world evidence on antiviral dispensing for influenza outpatients with underlying medical conditions (UMCs) is limited. We characterized dispensing among influenza outpatients aged <65 years with UMCs, comparing commercial and Medicaid coverage. Methods: We used outpatient encounter claims from the US MarketScan Commercial and Medicaid databases during October–April of the 2018–2019 through 2023–2024 influenza seasons and October–December 2024–2025. Eligible encounters included patients aged <65 years with a clinical influenza diagnosis, ≥1 UMC, and ≥12 months of continuous enrollment before diagnosis. Antiviral treatment was defined as dispensing of oseltamivir, peramivir, zanamivir, or baloxavir within 7 days of the encounter. We described demographic, clinical, and care-seeking characteristics and evaluated overall and same-day dispensing by insurance type. Results: Among 549 424 encounters, 268 463 (48.9%) were commercially insured (median age 19 years [interquartile range, IQR, 8–44]) and 280 961 (51.1%) were Medicaid insured (median age 10 years [IQR 5–18]). Chronic pulmonary disease was the most common UMC (88.0% and 81.8%). Antivirals were dispensed in 54.2% (commercial) and 53.7% (Medicaid) of encounters, almost exclusively oseltamivir. Same-day dispensing occurred in 91.1% of commercial and 81.4% of Medicaid encounters. Overall dispensing was lowest among patients with emergency department encounters or multiple outpatient visits; same-day dispensing was lowest among those with multiple UMCs, emergency department encounters, or multiple visits. Dispensing increased with age in commercial encounters but declined among adults with Medicaid. Conclusions: About half of higher-risk influenza outpatients received antivirals. Overall dispensing was similar by insurance type, but Medicaid patients and those with multiple UMCs had greater delays.
- 12 April 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (4) , 923-932
Modeling the Potential Impacts of Outpatient Antiviral Treatment in Reducing Influenza-Associated Hospitalizations in the United States
Background: Seasonal influenza causes an estimated 120 000 to 710 000 hospitalizations annually in the United States. Treatment with antiviral medications, such as oseltamivir, can reduce risks of hospitalization among people with influenza-associated illness. The US Centers for Disease Control and Prevention recommends initiating antiviral treatment as soon as possible for outpatients with suspected or confirmed influenza who have severe or progressive illness or are at higher risk of influenza complications. Methods: We developed a probabilistic model to estimate the impact of antiviral treatment in reducing hospitalizations among US outpatients with influenza. Parameters were informed by seasonal influenza surveillance platforms and stratified by age group and whether individuals had a condition associated with higher risk of influenza complications. We modeled different scenarios for influenza antiviral effectiveness and outpatient testing and prescribing practices, then compared our results with a baseline scenario in which antivirals were not used. Results: Across the modeled scenarios, antiviral treatment resulted in 1215 to 14 184 fewer influenza-associated hospitalizations on average when compared with the baseline scenario (0.2%–2.7% reduction). The greatest effects occurred among adults aged ≥65 years and individuals with conditions associated with higher risk of influenza complications. Modeling 50% improvements in access to care, testing, prescribing, and treatment resulted in greater potential impacts, with over 71 000 (13.3%) influenza-associated hospitalizations averted on average compared to baseline. Conclusions: Our results support recommendations to prioritize outpatient antiviral treatment among older adults and others at higher risk of influenza complications. Improving access to prompt testing and treatment among outpatients with suspected influenza could reduce hospitalizations substantially.
- 12 April 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (4) , 923-932
Modeling the Potential Impacts of Outpatient Antiviral Treatment in Reducing Influenza-Associated Hospitalizations in the United States
Background: Seasonal influenza causes an estimated 120 000 to 710 000 hospitalizations annually in the United States. Treatment with antiviral medications, such as oseltamivir, can reduce risks of hospitalization among people with influenza-associated illness. The US Centers for Disease Control and Prevention recommends initiating antiviral treatment as soon as possible for outpatients with suspected or confirmed influenza who have severe or progressive illness or are at higher risk of influenza complications. Methods: We developed a probabilistic model to estimate the impact of antiviral treatment in reducing hospitalizations among US outpatients with influenza. Parameters were informed by seasonal influenza surveillance platforms and stratified by age group and whether individuals had a condition associated with higher risk of influenza complications. We modeled different scenarios for influenza antiviral effectiveness and outpatient testing and prescribing practices, then compared our results with a baseline scenario in which antivirals were not used. Results: Across the modeled scenarios, antiviral treatment resulted in 1215 to 14 184 fewer influenza-associated hospitalizations on average when compared with the baseline scenario (0.2%–2.7% reduction). The greatest effects occurred among adults aged ≥65 years and individuals with conditions associated with higher risk of influenza complications. Modeling 50% improvements in access to care, testing, prescribing, and treatment resulted in greater potential impacts, with over 71 000 (13.3%) influenza-associated hospitalizations averted on average compared to baseline. Conclusions: Our results support recommendations to prioritize outpatient antiviral treatment among older adults and others at higher risk of influenza complications. Improving access to prompt testing and treatment among outpatients with suspected influenza could reduce hospitalizations substantially.
- 26 December 2021
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 62 (5) , 705-715
COVID-19 Vaccination and Intent Among Healthcare Personnel, U.S.
- 26 December 2021
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 62 (5) , 705-715
COVID-19 Vaccination and Intent Among Healthcare Personnel, U.S.
- Open Access
- 16 October 2020
- Published by SAGE Publications in The Diabetes Educator
- Vol. 46 (6) , 580-586
An Examination of Gender Differences in the National Diabetes Prevention Program’s Lifestyle Change Program
Purpose: The purpose of the study was to examine how gender was related to enrollment and number of sessions attended in the National Diabetes Prevention Program’s Lifestyle Change Program (DPP LCP). Methods: To better understand program uptake, a population of those who would be eligible for the LCP was compared to those who enrolled. Estimates of those eligible were computed using data from the National Health and Nutrition Examination Survey, whereas enrollment and sessions attended were computed using data from the Centers for Disease Control and Prevention’s Diabetes Prevention Recognition Program. Results: Results revealed that although similar numbers of males and females were eligible for the program, only 39 321 males versus 121 007 females had enrolled in the National DPP LCP by the end of 2017 (odds ratio = 3.20; 95% CI, 3.17-3.24). The gender differences persisted even when stratifying by age or race/ethnicity. In contrast, no significant gender differences were found between the average number of sessions attended for males (14.0) and females (13.8). Discussion: Results of the study can help inform efforts to market and tailor programs to appeal more directly to men and other groups that are underrepresented in the National DPP LCP.
- 16 October 2020
- Published by SAGE Publications in The Diabetes Educator
- Vol. 46 (6) , 580-586
Open AccessAn Examination of Gender Differences in the National Diabetes Prevention Program’s Lifestyle Change Program
Purpose: The purpose of the study was to examine how gender was related to enrollment and number of sessions attended in the National Diabetes Prevention Program’s Lifestyle Change Program (DPP LCP). Methods: To better understand program uptake, a population of those who would be eligible for the LCP was compared to those who enrolled. Estimates of those eligible were computed using data from the National Health and Nutrition Examination Survey, whereas enrollment and sessions attended were computed using data from the Centers for Disease Control and Prevention’s Diabetes Prevention Recognition Program. Results: Results revealed that although similar numbers of males and females were eligible for the program, only 39 321 males versus 121 007 females had enrolled in the National DPP LCP by the end of 2017 (odds ratio = 3.20; 95% CI, 3.17-3.24). The gender differences persisted even when stratifying by age or race/ethnicity. In contrast, no significant gender differences were found between the average number of sessions attended for males (14.0) and females (13.8). Discussion: Results of the study can help inform efforts to market and tailor programs to appeal more directly to men and other groups that are underrepresented in the National DPP LCP.